Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
27 Septiembre 2023 - 6:00AM
Business Wire
- Namodenoson robustly inhibits pancreatic carcinoma growth in
pre-clinical studies, via inhibition of KRAS and Wnt
pathways
- Poster summarizing the inhibitory effect of Namodenoson in
pancreatic carcinoma is presented today at the AACR
conference
- Exploratory Phase II pancreatic cancer study protocol has
been developed and is to be submitted to ethical committees in
Israel and the U.S.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address oncology, inflammatory and liver
diseases, today announced that its study titled “Namodenoson
Inhibits the Growth of Pancreatic Carcinoma via De-regulation of
the Wnt/β-catenin Signaling Pathway” has been accepted for a poster
presentation at the AACR Special Conference on Pancreatic Cancer,
held from September 27-30, 2023, in Boston, Massachusetts.
The pre-clinical studies presented in the poster used advanced
pancreatic carcinoma patient cells that were treated with
Namodenoson both in tissue cultures and in in vivo studies.
Namodenoson treatment resulted in a significant growth inhibition
and de-regulation of two signal transduction pathways, the Wnt and
the KRAS, both of which are responsible for the etiology and
pathology of this devastating disease.
Can-Fite completed the development of an exploratory Phase II
protocol in patients with pancreatic carcinoma who have failed
first line treatment and plans to shortly submit it for approval to
medical sites in Israel and the U.S. Safety and efficacy endpoints
including objective response, progression-free survival, duration
of response, disease control, and overall survival will be
monitored.
“The robust inhibition of pancreatic carcinoma growth both in
vitro and in vivo, together with the definitive mechanism of action
is a strong basis for evaluating Namodenoson in patients with
pancreatic carcinoma where chemotherapeutic drugs have a very
limited effect. We are very happy that the AACR granted us the
opportunity to present these encouraging data and to discuss the
very important results with the leading global experts in this
field,” stated Prof. Pnina Fishman, CSO & Executive Chairman of
Can-Fite.
About Pancreatic Cancer
The highest incidence rates for pancreatic cancer are in Asia,
Europe, and North America. According to the American Society of
Clinical Oncology (ASCO), in 2020, an estimated 496,000 people were
diagnosed with pancreatic cancer globally and an estimated 466,000
died from the disease. The 5-year survival rate for people with
pancreatic cancer in the U.S. is 11%. Acumen Research estimates the
global pancreatic cancer therapeutics market was valued at
approximately $3.6 billion in 2021 and is projected to grow to
approximately $6.6 billion by 2030.
About Namodenoson
Namodenoson was evaluated in Phase 2 trials for two indications,
as a second line treatment for hepatocellular carcinoma (HCC), and
as a treatment for non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic steatohepatitis (NASH). It is currently in a Phase 2b
trial for steatotic liver disease and a pivotal Phase 3 for HCC.
Namodenoson is a small orally bioavailable drug that binds with
high affinity and selectivity to the A3 adenosine receptor (A3AR).
A3AR is highly expressed in diseased cells whereas low expression
is found in normal cells. This differential effect accounts for the
excellent safety profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, and inflammatory disease. The
Company’s lead drug candidate, Piclidenoson recently reported
topline results in a Phase III trial for psoriasis and is expected
to commence a pivotal Phase III. Can-Fite’s cancer and liver drug,
Namodenoson, is being evaluated in a Phase IIb trial for the
treatment of steatotic liver disease (SLD), a Phase III pivotal
trial for hepatocellular carcinoma (HCC), and the Company is
planning a Phase IIa study in pancreatic cancer. Namodenoson has
been granted Orphan Drug Designation in the U.S. and Europe and
Fast Track Designation as a second line treatment for HCC by the
U.S. Food and Drug Administration. Namodenoson has also shown proof
of concept to potentially treat other cancers including colon,
prostate, and melanoma. CF602, the Company’s third drug candidate,
has shown efficacy in the treatment of erectile dysfunction. These
drugs have an excellent safety profile with experience in over
1,600 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. All
statements in this communication, other than those relating to
historical facts, are “forward looking statements”. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters.
Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made.
Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to known and
unknown risks, uncertainties and other factors that may cause
Can-Fite’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Important factors that could cause actual results,
performance or achievements to differ materially from those
anticipated in these forward-looking statements include, among
other things, our history of losses and needs for additional
capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of
cash flows and inability to meet working capital needs; the
initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into
clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our
product candidates, and the timing of other regulatory filings and
approvals; the clinical development, commercialization and market
acceptance of our product candidates; our ability to establish and
maintain strategic partnerships and other corporate collaborations;
the implementation of our business model and strategic plans for
our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights
covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of
others; competitive companies, technologies and our industry; risks
related to the COVID-19 pandemic and the Russian invasion of
Ukraine; risks related to not satisfying the continued listing
requirements of NYSE American; and statements as to the impact of
the political and security situation in Israel on our business.
More information on these risks, uncertainties and other factors is
included from time to time in the “Risk Factors” section of
Can-Fite’s Annual Report on Form 20-F filed with the SEC on March
30, 2023 and other public reports filed with the SEC and in its
periodic filings with the TASE. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Can-Fite
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230927971749/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De May 2023 a May 2024